EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

DelveInsight’s “EGFR Inhibitor Market Insights, Epidemiology, and Market Forecast-2034” report provides an in-depth analysis of the EGFR Inhibitor market, including historical and projected epidemiology trends, as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To explore the EGFR Inhibitor market outlook, drug uptake, treatment landscape, and epidemiology trends, click here: EGFR Inhibitor Market Forecast.

Key Highlights of the EGFR Inhibitor Market Report

• The EGFR Inhibitor market is projected to grow at a notable CAGR during the period 2020–2034.
• June 2025: Dizal completed enrollment for the Phase III WU-KONG28 trial evaluating oral sunvozertinib as a first-line therapy for NSCLC patients with EGFR exon 20 insertion mutations across 16 countries.
• April 2025: CSPC Pharmaceuticals is advancing SYS6010, an anti-EGFR ADC, into its first Phase III trial following initial clinical success. This aligns with developments by ALX Oncology (ALX2004) and Lepu Biopharma (MRG003), highlighted at ASCO 2025.
• According to the SEER database, approximately 64,050 new pancreatic cancer cases are expected in 2023. EGFR alterations are observed in 3.22% of colorectal carcinoma patients, with mutations in 2.33% of cases.
• Resistance to EGFR inhibitors develops in most patients after 10–11 months, despite an initial response rate of around 70% (Zubair et al., 2023).

Key EGFR Inhibitor Companies: Merus, Cullinan Oncology/Taiho Pharma, Suzhou Puhe Pharmaceutical, TWi Biotechnology, and others.
Key EGFR Inhibitor Therapies: Petosemtamab (MCLA-158), Zipalertinib, YK-029A, AC-701, and others.

The market is expected to expand due to increasing disease prevalence, heightened awareness, and emerging pipeline therapies across multiple stages of development.

EGFR Inhibitor Overview

EGFR inhibitors are targeted therapies designed to block Epidermal Growth Factor Receptor (EGFR) signaling, which is overactive or mutated in certain cancers, leading to uncontrolled cell proliferation.

Get a free sample report for EGFR Inhibitor Market Forecast, Size & Share Analysis

EGFR Inhibitor Epidemiology

The report analyzes historical, current, and projected epidemiology in the 7MM from 2020–2034, including diagnosed patient pools, disease severity, gender-specific prevalence, and episodic versus chronic cases.

EGFR Inhibitor Epidemiology Segmentation:

• Total prevalence
• Prevalence by severity
• Gender-specific prevalence
• Diagnosed episodic vs chronic cases

Download the report to explore the key epidemiology drivers @ EGFR Inhibitor Epidemiology Forecast.

EGFR Inhibitor Drugs Uptake and Pipeline Development

• Tracks market uptake of recently launched or anticipated therapies.
• Evaluates patient adoption, drug sales, and reasons for highest usage.
• Provides insights into pipeline candidates, clinical stages, collaborations, acquisitions, licensing, patents, and emerging therapies.

EGFR Inhibitor Therapies and Key Companies:

• Petosemtamab (MCLA-158): Merus
• MCLA-129: Merus
• Zipalertinib: Cullinan Oncology/Taiho Pharma
• YK-029A: Suzhou Puhe Pharmaceutical
• AC-701: TWi Biotechnology

Explore therapies poised to capture significant market share @ EGFR Inhibitor Treatment Landscape.

EGFR Inhibitor Market Strengths & Opportunities

Strengths:

• MCLA-129 targets EGFR and c-MET, offering potential in lung cancer.
• First- to third-generation EGFR inhibitors significantly improve prognosis and treatment outcomes.

Opportunities:

• Overcoming intrinsic and acquired resistance in primary and recurrent cancers.
• Novel approaches, including targeted protein degradation, present new directions for next-generation EGFR inhibitors.

Scope of the EGFR Inhibitor Market Report

• Study Period: 2020–2034
• Coverage: 7MM (U.S., EU5, Japan)
• Key Companies: Merus, Cullinan Oncology/Taiho Pharma, Suzhou Puhe Pharmaceutical, TWi Biotechnology, and others
• Therapies: Petosemtamab, Zipalertinib, YK-029A, AC-701, and others
• Analysis: Market dynamics, drivers, barriers, competitive intelligence (SWOT, PESTLE, Porter’s Five Forces, BCG), unmet needs, KOL insights, market access, and reimbursement

Learn more about EGFR Inhibitor companies working in the treatment market @ EGFR Inhibitor Clinical Trials and Therapeutic Assessment.

Table of Contents

1. EGFR Inhibitor Market Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Patient Share Overview
5. Market Overview at a Glance
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Country-Specific Patient Population
9. Current Treatment and Medical Practices
10. Unmet Needs
11. Emerging Therapies
12. Market Outlook
13. Country-Wise Market Analysis (2020–2034)
14. Market Access and Reimbursement
15. Market Drivers
16. Market Barriers
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.